Skip to Content

Join the 'Stalevo 125' group to help and get support from people like you.

Stalevo 125 News

Inhaled Version of Parkinson's Drug May Help Keep Symptoms at Bay

Posted 12 Oct 2016 by Drugs.com

WEDNESDAY, Oct. 12, 2016 – An inhaled version of the Parkinson's drug levodopa can help when patients experience symptoms between doses of the pill form of the medication, a new, small study finds. Levodopa can control the tremors, rigidity and difficulty maintaining balance and coordination associated with Parkinson's disease. However, within two years, as many as half of all patients have rapid and unexpected loss of motor control during "off" periods, when the drug wears off between doses, the researchers explained. "Off periods are considered one of the greatest unmet medical needs in the treatment of Parkinson's, and typically increase in frequency during the course of the disease," said lead researcher Michael Lipp. He is vice president of pharmaceutical development and technical operations at Acorda Therapeutics, the drug's maker and funder of the study. Inhaled levodopa could ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Rytary, Parkinsonian Tremor, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Dopar, Stalevo 50, Stalevo 125, Parkinson's Disease Psychosis, Atamet, Larodopa, Duopa

Study Questions Use of Physical Therapy for Early Parkinson's

Posted 19 Jan 2016 by Drugs.com

TUESDAY, Jan. 19, 2016 – Physical therapy might not benefit people with mild-to-moderate Parkinson's disease, a new study suggests. Parkinson's disease is a movement disorder that interferes with the ability to do daily tasks. Typically, physical therapy is used in the later stages of the disease, but this study assessed its effectiveness in earlier stages. Researchers randomly assigned 762 patients with mild-to-moderate Parkinson's to either physical therapy and occupational therapy, or a "control" group with no therapy. Over eight weeks, the patients in the therapy group did about four 58-minute sessions. After three months, there was no difference between the therapy group and the control group in the ability to do daily tasks, the study found. The results were published online Jan. 19 in the journal JAMA Neurology. It's possible that mild-to-moderate Parkinson's disease may not ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Rytary, Parkinsonian Tremor, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Dopar, Stalevo 50, Stalevo 125, Atamet, Larodopa, Duopa, Stalevo 75

New Clues to Easing Side Effects From Parkinson's Drug

Posted 18 Nov 2015 by Drugs.com

WEDNESDAY, Nov. 18, 2015 – The drug levodopa is a leading treatment for Parkinson's disease, but for most patients the medication also brings debilitating side effects. Now, scientists say animal studies are pointing to a compound that might reduce those unwanted effects. "If clinical trials confirm our preliminary findings, the eventual drug developed could make a significant improvement in the quality of life for people with Parkinson's disease," lead researcher D. James Surmeier, chair of physiology at Northwestern University School of Medicine in Chicago, said in a university news release. According to the researchers, Parkinson's disease affects more than one million Americans, and that number is expected to double by 2030. Levodopa is widely used to treat the stiffness, tremors and poor muscle control caused by the illness. But the drug can also trigger uncontrolled movement – ... Read more

Related support groups: Parkinson's Disease, Sinemet, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Rytary, Parkinsonian Tremor, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Dopar, Stalevo 50, Stalevo 125, Atamet, Larodopa, Duopa, Stalevo 75

Parkinson's Drug Shows Promise Against Macular Degeneration

Posted 12 Nov 2015 by Drugs.com

THURSDAY, Nov. 12, 2015 – A common Parkinson's disease medication might hold potential for preventing or treating macular degeneration, the leading cause of vision loss in the elderly, new research suggests. At this stage, no one is recommending that patients take the drug, levodopa (L-dopa), to thwart eye disease. But the findings are intriguing, researchers said. "Patients taking L-dopa for any reason are much less likely to develop age-related macular degeneration. If they do, they develop the disease much later in life than those not taking L-dopa," said study lead author Brian McKay, an associate professor of ophthalmology and vision science at the University of Arizona. However, the study doesn't actually prove that levodopa causes a lower incidence of age-related macular degeneration. It only uncovered an association between the two. Age-related macular degeneration affects ... Read more

Related support groups: Parkinson's Disease, Sinemet, Macular Degeneration, Levodopa, Carbidopa/Levodopa, Stalevo, Sinemet CR, Rytary, Parkinsonian Tremor, Diagnosis and Investigation, Stalevo 100, Parkinsonism, Parcopa, Carbidopa/Entacapone/Levodopa, Stalevo 200, Dopar, Stalevo 50, Stalevo 125, Atamet, Larodopa

FDA Medwatch Alert: Entacapone: Drug Safety Communication - FDA Review Found No Increased Cardiovascular Risks

Posted 28 Oct 2015 by Drugs.com

Including Comtan (entacapone) and Stalevo (entacapone, carbidopa, and levodopa) ISSUE: An FDA safety review has found no clear evidence of an increased risk of heart attacks, stroke, or other cardiovascular events associated with the use of entacapone for the treatment of Parkinson’s disease. As a result, recommendations for using Comtan (entacapone) and Stalevo (a combination of entacapone, carbidopa, and levodopa) will remain the same in the drug labels. FDA alerted patients and health care professionals about a possible increased risk for cardiovascular events and death with Stalevo in August 2010. This possible safety issue was observed in a clinical trial called the Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease (STRIDE-PD) and in a meta-analysis that combined the cardiovascular-related findings from 15 clinical trials comparing Stalevo to carbidopa/levodopa. Car ... Read more

Related support groups: Parkinson's Disease, Stalevo, Comtan, Entacapone, Stalevo 100, Carbidopa/Entacapone/Levodopa, Stalevo 200, Stalevo 75, Stalevo 150, Stalevo 50, Stalevo 125

Ask a Question

Further Information

Related Condition Support Groups

Parkinson's Disease

Stalevo 125 Patient Information at Drugs.com